561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Merger Agreement with GlaxoSmithKline LLC Announced by RAPT Therapeutics
Enters Agreement to Acquire RAPT Therapeutics
Investor Presentation
Dr. William Ho Departure - Chief Medical Officer to Leave RAPT Therapeutics
Reports Third Quarter 2025 Financial Results and Recent Highlights
RAPT Therapeutics Announces Underwritten Public Offering of 8.33M Shares
Financial Results, Press Release
Q3
Q2
Q1
FY 2024
FY 2023
Effectiveness Notice
Solicitation/Recommendation Statement
Tender Offer Statement by Third Party
Schedule 14D-9C Solicitation/Recommendation Statement Communication
Tender Offer Statement by Issuer
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
S-8 POS
Amended Schedule 14D-9 Solicitation/Recommendation Statement